12:00 AM
 | 
Nov 23, 2009
 |  BioCentury  |  Politics, Policy & Law

Tallying the Costs

Tallying the Costs

Senate provision Estimated cost to drug companies over 10 years
Biosimilars pathway - would provide 12 years of exclusivity for branded biologics and one year of exclusivity for the first interchangeable biosimilar...

Read the full 193 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >